AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...
Nasal Flu Vaccine Is Approved for At-Home Use
The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...
US FDA approves AstraZeneca's flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
AstraZeneca: TROPION-Breast01 Phase III Trial Fails To Achieve Statistical Significance
Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...
AstraZeneca drug fails to extend lives of breast cancer patients significantly
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...
Zawya4h
AstraZeneca to pump $50mln into new investments in Egypt
Arab Finance: AstraZeneca Egypt is planning to inject $50 million into new investments in Egypt, equivalent to nearly 50% of the company’s capital, the firm’s Country President Hatem Werdany stated.
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
WAPT1d
FDA approves first flu vaccine that can be self-administered at home
FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...